10-Q quarterly report · filed Nov 3, 2026

Denali Therapeutics Inc. (DNLI) Q3 2026 10-Q Quarterly Report

Short answer

Denali Therapeutics Inc. (DNLI) filed its Q3 2026 10-Q quarterly report on Nov 3, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $18M with net income of $70M.

Q3 2026 key financials · XBRL

Revenue
$18M
+393.3% QoQ
Net income
$70M
+155.3% YoY · +155.0% QoQ
Operating margin
-713.0%
EPS (diluted)
$0.38
+151.4% YoY · +155.9% QoQ

Source: XBRL data from the Denali Therapeutics Inc. (DNLI) Q3 2026 10-Q on SEC EDGAR. USD.

Denali Therapeutics Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly revenue $17.8M, versus $0 prior year, from AVLAYAH commercialization
  • Operating loss $126.8M, operating margin -713.1% versus not meaningful prior year
  • Net income $70.1M versus $126.9M loss, including $194.0M priority review voucher gain
  • Cash, equivalents and marketable securities $1.0B; operating cash use $345.6M year-to-date
  • AVLAYAH revenue not expected to offset expenses near term; zafinofusp BLA submission remains on track for 2027

Risk Factors

  • No material changes to risk factors previously disclosed in the 2025 Form 10-K and 2026 quarterly filings

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Denali Therapeutics Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.